Johnson & Johnson Chief Financial Officer Joseph Wolk said the company sees a "clear line of sight to double digits" in growth by the end of the decade, moving well past its previous long-term target range of 5% to 7%, during remarks at the Deutsche Bank Healthcare Summit on September 17, 2026.
The upbeat commentary came as J&J shares traded near their 52-week high of $281. The stock closed at $269.99 on September 18, delivering a 54% return over the past year. The company's market capitalization stands at $645 billion with a trailing price-to-earnings ratio of 31.
Wolk reiterated the company's commitment to annual sales above $100 billion and outlined free cash flow of $21 billion expected in 2026, which he described as a peak before further expansion. He confirmed that an investor day is scheduled for December 8, where management plans to provide additional detail on multi-year cash-flow and growth-rate projections.
The U.S. investment commitment totals $55 billion over four years, with roughly 1.5 years already elapsed. Geographic revenue remains approximately 50/50 between the United States and international markets, though Wolk noted the split leans slightly toward non-U.S. at about 48/52. A calendar quirk in 2026 — a 53rd week — could add 1.5 to 2 percentage points to reported growth.
On the loss-of-exclusivity front, Wolk quantified that about $4 billion to $4.5 billion in revenue will face patent expiry pressure in 2027. Xarelto accounts for roughly $2 billion of that, the pulmonary arterial hypertension franchise approximately $1.5 billion, and Simponi combined with Stelara about $1 billion.
Wolk highlighted the pharmaceutical portfolio's oncology ambition, targeting $50 billion in cancer drug sales — up from roughly $30 billion currently — excluding M&A contributions. He pointed to multiple myeloma as a standout segment, noting that more than 85% of patients are on J&J therapies. The company's Darzalex Faspro formulation has cut infusion times from three to five hours down to just 15 minutes, and patients who began early therapy seven to eight years ago remain alive today, compared with historical life expectancies of one to two years.
In immunology, new product launches are showing rapid uptake. Icotrokinra, launched for psoriasis, treated 17,000 patients within five months and has secured coverage from all three major U.S. payers. Tremfya grew 80% in the second quarter following five years on the market, with atopic dermatitis cited as a market roughly four times larger than psoriasis. The company also received approval for Imaavy (nipocalimab) for myasthenia gravis and warm autoimmune hemolytic anemia.
Med Tech platform scale was another focus area. Wolk said the segment now encompasses 28 platforms each generating more than $1 billion in revenue. Pulsed field ablation via Varipulse has treated more than 100,000 patients worldwide and is backed by 6,300 installed CARTO mapping systems. The company announced its first robotics account sign-on with Memorial Hermann in Texas for the Ottava surgical robot.
J&J also disclosed that the $5.5 billion talc litigation settlement has been substantially resolved and came in below earlier bankruptcy-phase expectations.
The company is scheduled to share further guidance at its December 8 investor day.
